CN103796679B - 抗-α突触核蛋白结合分子 - Google Patents
抗-α突触核蛋白结合分子 Download PDFInfo
- Publication number
- CN103796679B CN103796679B CN201280039104.2A CN201280039104A CN103796679B CN 103796679 B CN103796679 B CN 103796679B CN 201280039104 A CN201280039104 A CN 201280039104A CN 103796679 B CN103796679 B CN 103796679B
- Authority
- CN
- China
- Prior art keywords
- antibody
- alpha
- synapse nucleoprotein
- fab
- seq
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
- G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
- G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/28—Neurological disorders
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/28—Neurological disorders
- G01N2800/2814—Dementia; Cognitive disorders
- G01N2800/2828—Prion diseases
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/28—Neurological disorders
- G01N2800/2835—Movement disorders, e.g. Parkinson, Huntington, Tourette
Abstract
Description
Kabat | Chothia | |
VH CDR1 | 31-35 | 26-32 |
VH CDR2 | 50-65 | 52-58 |
VH CDR3 | 95-102 | 95-102 |
VL CDR1 | 24-34 | 26-32 |
VL CDR2 | 50-56 | 50-52 |
VL CDR3 | 89-97 | 91-96 |
Claims (68)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201161500580P | 2011-06-23 | 2011-06-23 | |
US61/500,580 | 2011-06-23 | ||
PCT/US2012/043701 WO2012177972A1 (en) | 2011-06-23 | 2012-06-22 | Anti-alpha synuclein binding molecules |
Publications (2)
Publication Number | Publication Date |
---|---|
CN103796679A CN103796679A (zh) | 2014-05-14 |
CN103796679B true CN103796679B (zh) | 2016-10-19 |
Family
ID=47422964
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201280039104.2A Active CN103796679B (zh) | 2011-06-23 | 2012-06-22 | 抗-α突触核蛋白结合分子 |
Country Status (23)
Country | Link |
---|---|
US (3) | US9580493B2 (zh) |
EP (1) | EP2723379B1 (zh) |
JP (2) | JP2014528695A (zh) |
KR (1) | KR101976887B1 (zh) |
CN (1) | CN103796679B (zh) |
AU (1) | AU2012272790B2 (zh) |
BR (1) | BR112013033258B1 (zh) |
CA (1) | CA2839563C (zh) |
CY (1) | CY1121392T1 (zh) |
DK (1) | DK2723379T3 (zh) |
EA (1) | EA030777B9 (zh) |
ES (1) | ES2699801T3 (zh) |
HR (1) | HRP20181553T1 (zh) |
HU (1) | HUE041391T2 (zh) |
IL (1) | IL230028B (zh) |
LT (1) | LT2723379T (zh) |
MX (1) | MX357193B (zh) |
PL (1) | PL2723379T3 (zh) |
PT (1) | PT2723379T (zh) |
SI (1) | SI2723379T1 (zh) |
TR (1) | TR201815563T4 (zh) |
WO (1) | WO2012177972A1 (zh) |
ZA (1) | ZA201309623B (zh) |
Families Citing this family (34)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DK2370466T3 (en) | 2008-12-19 | 2015-08-03 | Univ Zuerich | Humane anti-alpha-synuclein-autoantistoffer |
BR112013033258B1 (pt) | 2011-06-23 | 2022-09-20 | University Of Zurich | Anticorpo isolado ou fragmento de ligação ao antígeno do mesmo que se liga a alfasinucleína, composição e seus usos |
US9534044B2 (en) * | 2013-02-28 | 2017-01-03 | United Arab Emirates University | Alpha-synuclein antibodies and uses thereof |
JP6592426B2 (ja) | 2013-03-15 | 2019-10-16 | バイオジェン・エムエイ・インコーポレイテッドBiogen MA Inc. | 無塩条件下で疎水性相互作用クロマトグラフィーを使用するタンパク質精製 |
JP6037043B2 (ja) * | 2014-08-22 | 2016-11-30 | 日東紡績株式会社 | TRACP−5b(酒石酸抵抗性酸性フォスファターゼ5b)に特異的なタンパク定量法 |
US9732148B2 (en) | 2014-10-16 | 2017-08-15 | Genentech, Inc. | Anti-α-synuclein antibodies and methods of use |
GB201512203D0 (en) | 2015-07-13 | 2015-08-19 | Lundbeck & Co As H | Agents,uses and methods |
EP3430397B1 (en) | 2016-03-14 | 2022-02-23 | Biogen International Neuroscience GmbH | Antibody-dependent cell-mediated phagocytosis assay for reliably measuring uptake of aggregated proteins |
CN116120445A (zh) | 2016-06-02 | 2023-05-16 | 麦迪穆有限责任公司 | 针对α-突触核蛋白的抗体及其用途 |
WO2018022479A1 (en) | 2016-07-25 | 2018-02-01 | Biogen Ma Inc. | Anti-hspa5 (grp78) antibodies and uses thereof |
AR110074A1 (es) * | 2016-11-15 | 2019-02-20 | H Lundbeck As | Agentes, usos y métodos para el tratamiento de la sinucleinopatía |
EP3562840A1 (en) | 2016-12-16 | 2019-11-06 | Biogen MA Inc. | Stabilized proteolytically activated growth differentiation factor 11 |
WO2018109058A1 (en) | 2016-12-16 | 2018-06-21 | H. Lundbeck A/S | Agents, uses and methods |
US10364286B2 (en) | 2016-12-22 | 2019-07-30 | H. Lundbeck A/S | Monoclonal anti-alpha-synuclein antibodies for preventing tau aggregation |
JP2018109560A (ja) | 2017-01-04 | 2018-07-12 | オムロンオートモーティブエレクトロニクス株式会社 | 走査式距離測定装置 |
CA3051839A1 (en) | 2017-02-17 | 2018-08-23 | Bristol-Myers Squibb Company | Antibodies to alpha-synuclein and uses thereof |
JOP20190227A1 (ar) * | 2017-03-31 | 2019-09-30 | Biogen Int Neuroscience Gmbh | تركيبات وطرق لعلاج اعتلالات السينوكلين |
WO2018237338A1 (en) * | 2017-06-23 | 2018-12-27 | Denali Therapeutics Inc. | ANTI-ALPHA-SYNCUCIN ANTIBODIES AND METHODS OF USE |
CN111225923A (zh) * | 2017-08-02 | 2020-06-02 | 思瑞麦科生物科技公司 | 结合活性α突触核蛋白的抗体 |
EP3672635A4 (en) | 2017-08-23 | 2021-05-12 | The Trustees of The University of Pennsylvania | MONOCLONAL ANTIBODIES AGAINST PATHOLOGICAL ALPHA-SYNUCLEIN, AND METHODS USING THEM |
CA3076313A1 (en) * | 2017-09-28 | 2019-04-04 | Prothena Biosciences Limited | Dosing regimes for treatment of synucleinopathies |
EP3725802A4 (en) * | 2017-11-17 | 2021-08-11 | ABL Bio Inc. | ANTIBODIES TO ALPHA SYNUCLEIN AND USES THEREOF |
GB201720975D0 (en) * | 2017-12-15 | 2018-01-31 | Ucb Biopharma Sprl | Anti-alpha synuclein antibodies |
GB201720970D0 (en) * | 2017-12-15 | 2018-01-31 | Ucb Biopharma Sprl | Antibodies |
CN112839710A (zh) | 2018-08-09 | 2021-05-25 | 霍夫曼-拉罗奇有限公司 | 帕金森氏病的确定 |
CA3117409A1 (en) | 2018-10-29 | 2020-05-07 | Biogen Ma Inc. | Humanized and stabilized fc5 variants for enhancement of blood brain barrier transport |
TWI734279B (zh) * | 2018-12-14 | 2021-07-21 | 美商美國禮來大藥廠 | 抗α-突觸核蛋白抗體及其用途 |
EP3998286A4 (en) * | 2019-07-11 | 2023-04-26 | Wuhan Yzy Biopharma Co., Ltd. | QUAD VALUE SYMMETRIC BISPECIFIC ANTIBODIES |
NL2025332B1 (en) * | 2020-04-10 | 2021-10-26 | Syngle Therapeutics B V | Novel alpha-synuclein binding antibodies, or antigen binding portions thereof. |
WO2021214277A1 (en) | 2020-04-24 | 2021-10-28 | F. Hoffmann-La Roche Ag | Enzyme and pathway modulation with sulfhydryl compounds and their derivatives |
MX2022016005A (es) | 2020-06-26 | 2023-02-02 | Bioarctic Ab | Anticuerpos de fijacion a protofibrillas de \03b1-sinucleina. |
CN112920274A (zh) * | 2021-03-17 | 2021-06-08 | 江苏贝格尔生物医药有限公司 | 一种检测alpha-synuclein蛋白的鼠单克隆抗体及其应用 |
WO2023099788A1 (en) | 2021-12-03 | 2023-06-08 | Neurimmune Ag | Novel potency assay for antibody-based drugs and useful means therefor |
CN117106081A (zh) * | 2023-09-28 | 2023-11-24 | 北京凯祥弘康生物科技有限公司 | 一种抗nfl蛋白的捕获抗体 |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2005060641A2 (en) * | 2003-12-15 | 2005-07-07 | Alexion Pharmaceuticals, Inc. | Engineered templates and their use in single primer amplification |
WO2010032059A2 (en) * | 2008-09-19 | 2010-03-25 | Medimmune Llc | Targeted binding agents directed to cd105 and uses thereof |
WO2010069603A1 (en) * | 2008-12-19 | 2010-06-24 | Neurimmune Therapeutics Ag | Human anti-alpha-synuclein autoantibodies |
Family Cites Families (130)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4741900A (en) | 1982-11-16 | 1988-05-03 | Cytogen Corporation | Antibody-metal ion complexes |
WO1986005807A1 (en) | 1985-04-01 | 1986-10-09 | Celltech Limited | Transformed myeloma cell-line and a process for the expression of a gene coding for a eukaryotic polypeptide employing same |
GB8601597D0 (en) | 1986-01-23 | 1986-02-26 | Wilson R H | Nucleotide sequences |
GB8607679D0 (en) | 1986-03-27 | 1986-04-30 | Winter G P | Recombinant dna product |
DE3853515T3 (de) | 1987-05-21 | 2005-08-25 | Micromet Ag | Multifunktionelle proteine mit vorbestimmter zielsetzung. |
US5892019A (en) | 1987-07-15 | 1999-04-06 | The United States Of America, As Represented By The Department Of Health And Human Services | Production of a single-gene-encoded immunoglobulin |
GB8717430D0 (en) | 1987-07-23 | 1987-08-26 | Celltech Ltd | Recombinant dna product |
AU631545B2 (en) | 1988-04-15 | 1992-12-03 | Protein Design Labs, Inc. | Il-2 receptor-specific chimeric antibodies |
DE68921982T4 (de) | 1988-06-14 | 1996-04-25 | Cetus Oncology Corp | Kupplungsmittel und sterisch gehinderte, mit disulfid gebundene konjugate daraus. |
IL162181A (en) | 1988-12-28 | 2006-04-10 | Pdl Biopharma Inc | A method of producing humanized immunoglubulin, and polynucleotides encoding the same |
US5116964A (en) | 1989-02-23 | 1992-05-26 | Genentech, Inc. | Hybrid immunoglobulins |
US5225538A (en) | 1989-02-23 | 1993-07-06 | Genentech, Inc. | Lymphocyte homing receptor/immunoglobulin fusion proteins |
IE63847B1 (en) | 1989-05-05 | 1995-06-14 | Res Dev Foundation | A novel antibody delivery system for biological response modifiers |
JP3068180B2 (ja) | 1990-01-12 | 2000-07-24 | アブジェニックス インコーポレイテッド | 異種抗体の生成 |
US5314995A (en) | 1990-01-22 | 1994-05-24 | Oncogen | Therapeutic interleukin-2-antibody based fusion proteins |
AU654811B2 (en) | 1990-03-20 | 1994-11-24 | Trustees Of Columbia University In The City Of New York, The | Chimeric antibodies with receptor binding ligands in place of their constant region |
ATE218889T1 (de) | 1990-11-09 | 2002-06-15 | Stephen D Gillies | Cytokine immunokonjugate |
MX9204374A (es) | 1991-07-25 | 1993-03-01 | Idec Pharma Corp | Anticuerpo recombinante y metodo para su produccion. |
FR2686087A1 (fr) | 1992-01-13 | 1993-07-16 | Inst Nat Sante Rech Med | Nouvel antigene lymphocytaire, anticorps correspondant et leurs applications. |
ES2301158T3 (es) | 1992-07-24 | 2008-06-16 | Amgen Fremont Inc. | Produccion de anticuerpos xenogenicos. |
CA2126967A1 (en) | 1992-11-04 | 1994-05-11 | Anna M. Wu | Novel antibody construct |
US5736137A (en) | 1992-11-13 | 1998-04-07 | Idec Pharmaceuticals Corporation | Therapeutic application of chimeric and radiolabeled antibodies to human B lymphocyte restricted differentiation antigen for treatment of B cell lymphoma |
DE669986T1 (de) | 1992-11-13 | 1996-10-10 | Idec Pharma Corp | Völlig unfunktionelle konsensus-kozak-sequenzen zur säugetier-exprimierung. |
US5676950A (en) | 1994-10-28 | 1997-10-14 | University Of Florida | Enterically administered recombinant poxvirus vaccines |
WO1996016085A1 (en) | 1994-11-18 | 1996-05-30 | Neurocrine Biosciences, Inc. | Methods for treatment of multiple sclerosis using peptide analogues at position 91 of human myelin basic protein |
CA2761116A1 (en) | 1995-04-27 | 1996-10-31 | Amgen Fremont Inc. | Human antibodies derived from immunized xenomice |
CA2219486A1 (en) | 1995-04-28 | 1996-10-31 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
GB9524973D0 (en) | 1995-12-06 | 1996-02-07 | Lynxvale Ltd | Viral vectors |
PT981637E (pt) | 1997-03-14 | 2005-09-30 | Biogen Idec Inc | Metodo para integrar genes em sitios especificos em celulas de mamifero atraves de recombinacao homologa e vectores para a realizacao do mesmo |
US20020086847A1 (en) | 1997-04-09 | 2002-07-04 | Mindset Biopharmaceuticals (Usa) | Recombinant antibodies specific for beta-amyloid ends, DNA encoding and methods of use thereof |
US8173127B2 (en) | 1997-04-09 | 2012-05-08 | Intellect Neurosciences, Inc. | Specific antibodies to amyloid beta peptide, pharmaceutical compositions and methods of use thereof |
CN1177616C (zh) | 1997-04-09 | 2004-12-01 | 曼德塞特生物制药公司 | 特异于β-淀粉状蛋白末端的重组抗体,编码它们的DNA及其使用方法 |
GB2339430A (en) | 1997-05-21 | 2000-01-26 | Biovation Ltd | Method for the production of non-immunogenic proteins |
US6703015B1 (en) | 1999-09-03 | 2004-03-09 | Ramot At Tel-Aviv University Ltd. | Filamentous bacteriophage displaying an β-amyloid epitope |
US7964192B1 (en) | 1997-12-02 | 2011-06-21 | Janssen Alzheimer Immunotherapy | Prevention and treatment of amyloidgenic disease |
TWI239847B (en) | 1997-12-02 | 2005-09-21 | Elan Pharm Inc | N-terminal fragment of Abeta peptide and an adjuvant for preventing and treating amyloidogenic disease |
US6913745B1 (en) | 1997-12-02 | 2005-07-05 | Neuralab Limited | Passive immunization of Alzheimer's disease |
US6761888B1 (en) | 2000-05-26 | 2004-07-13 | Neuralab Limited | Passive immunization treatment of Alzheimer's disease |
US7179892B2 (en) | 2000-12-06 | 2007-02-20 | Neuralab Limited | Humanized antibodies that recognize beta amyloid peptide |
US6750324B1 (en) | 1997-12-02 | 2004-06-15 | Neuralab Limited | Humanized and chimeric N-terminal amyloid beta-antibodies |
US6905686B1 (en) | 1997-12-02 | 2005-06-14 | Neuralab Limited | Active immunization for treatment of alzheimer's disease |
US6710226B1 (en) | 1997-12-02 | 2004-03-23 | Neuralab Limited | Transgenic mouse assay to determine the effect of Aβ antibodies and Aβ Fragments on alzheimer's disease characteristics |
US20080050367A1 (en) | 1998-04-07 | 2008-02-28 | Guriq Basi | Humanized antibodies that recognize beta amyloid peptide |
US7462605B2 (en) | 1998-01-23 | 2008-12-09 | Celmed Oncology (Usa), Inc. | Phosphoramidate compounds and methods of use |
AU3117799A (en) | 1998-03-30 | 1999-10-18 | Trustees Of The University Of Pennsylvania, The | Method of identifying, diagnosing and treating synuclein positive neurodegenerative disorders |
WO2000030680A1 (en) | 1998-11-23 | 2000-06-02 | Idec Pharmaceuticals Corporation | Tumor antigen-specific antibody-gp39 chimeric protein constructs |
JP2002534959A (ja) | 1998-12-08 | 2002-10-22 | バイオベーション リミテッド | 免疫原性タンパク質の改変方法 |
US6787637B1 (en) | 1999-05-28 | 2004-09-07 | Neuralab Limited | N-Terminal amyloid-β antibodies |
UA81216C2 (en) | 1999-06-01 | 2007-12-25 | Prevention and treatment of amyloid disease | |
CA2274414A1 (en) | 1999-06-11 | 2000-12-11 | Universite Laval | Dietary fish protein for use in restoring normal insulin function insulin-resistant individuals |
WO2001018169A2 (en) | 1999-09-03 | 2001-03-15 | Ramot University Authority For Applied Research & Industrial Development Ltd. | Agents and compositions and methods for diagnostic and/or treating or preventing plaque forming diseases |
US6713058B2 (en) | 1999-09-14 | 2004-03-30 | Milkhaus Laboratory, Inc. | Methods for alleviating symptoms associated with neuropathic conditions comprising administration of low levels of antibodies |
US6187309B1 (en) | 1999-09-14 | 2001-02-13 | Milkaus Laboratory, Inc. | Method for treatment of symptoms of central nervous system disorders |
US6294171B2 (en) | 1999-09-14 | 2001-09-25 | Milkhaus Laboratory, Inc. | Methods for treating disease states comprising administration of low levels of antibodies |
US6436401B1 (en) | 1999-09-14 | 2002-08-20 | Milkhaus Laboratory, Inc. | Methods for alleviating symptoms associated with diabetes and diabetic neuropathy comprising administration of low levels of antibodies |
CA2412494C (en) * | 2000-06-22 | 2012-10-23 | Genentech, Inc. | Agonist anti-trk-c monoclonal antibodies |
EP2082749A3 (en) | 2000-07-07 | 2010-06-30 | Bioarctic Neuroscience AB | Prevention and treatment of Alzheimer's disease |
US7858559B2 (en) | 2000-11-17 | 2010-12-28 | University Of Rochester | In vitro methods of producing and identifying immunoglobulin molecules in eukaryotic cells |
TWI255272B (en) | 2000-12-06 | 2006-05-21 | Guriq Basi | Humanized antibodies that recognize beta amyloid peptide |
US7700751B2 (en) | 2000-12-06 | 2010-04-20 | Janssen Alzheimer Immunotherapy | Humanized antibodies that recognize β-amyloid peptide |
IL157142A0 (en) | 2001-01-29 | 2004-02-08 | Idec Pharma Corp | Modified antibodies and methods of use |
US7319139B2 (en) | 2001-01-29 | 2008-01-15 | Biogen Idec, Inc. | TAG-72 specific CH2 domain deleted antibodies |
ITPV20010007U1 (it) | 2001-07-19 | 2003-01-19 | Maruscia Food Specialties Comp | Contenitore per profilattico nuovo e usato |
US7771722B2 (en) | 2001-08-17 | 2010-08-10 | Eli Lilly And Company | Assay method for alzheimer's disease |
US20030157641A1 (en) | 2001-11-16 | 2003-08-21 | Idec Pharmaceuticals Corporation | Polycistronic expression of antibodies |
GB0203446D0 (en) * | 2002-02-14 | 2002-04-03 | Univ Lancaster | Detection and/or monitoring of synuclein-related diseases |
MY139983A (en) | 2002-03-12 | 2009-11-30 | Janssen Alzheimer Immunotherap | Humanized antibodies that recognize beta amyloid peptide |
US20110200609A1 (en) | 2002-09-12 | 2011-08-18 | The Regents Of The University Of California | Monoclonal antibodies specific for pathological amyloid aggregates common to amyloids formed from proteins of differing sequence |
US8506959B2 (en) | 2002-11-01 | 2013-08-13 | Neotope Biosciences Limited | Prevention and treatment of synucleinopathic and amyloidogenic disease |
TW200509968A (en) | 2002-11-01 | 2005-03-16 | Elan Pharm Inc | Prevention and treatment of synucleinopathic disease |
WO2004048571A1 (ja) | 2002-11-22 | 2004-06-10 | Chugai Seiyaku Kabushiki Kaisha | 病巣組織に対する抗体 |
US20060240485A1 (en) | 2003-04-24 | 2006-10-26 | Universitat Zurich | Method of monitoring immunotherapy |
TWI374893B (en) | 2003-05-30 | 2012-10-21 | Janssen Alzheimer Immunotherap | Humanized antibodies that recognize beta amyloid peptide |
WO2005018424A2 (en) | 2003-08-18 | 2005-03-03 | Research Foundation For Mental Hygiene, Inc. | Antibodies specific for fibrillar amyloid and a procedure to detect fibrillar amyloid deposits |
CA2536408A1 (en) | 2003-08-22 | 2005-03-03 | Biogen Idec Ma Inc. | Improved antibodies having altered effector function and methods for making the same |
US20070031416A1 (en) | 2003-09-09 | 2007-02-08 | Takeda Pharmaceutical Company Limited | Use of antibody |
US7674599B2 (en) * | 2003-11-08 | 2010-03-09 | Elan Pharmaceuticals, Inc. | Methods of using antibodies to detect alpha-synuclein in fluid samples |
BRPI0507856A (pt) | 2004-02-23 | 2007-07-10 | Lilly Co Eli | composição farmacêutica, e, processo para preparar o anticorpo abeta |
CA2564432A1 (en) | 2004-04-27 | 2005-11-10 | Juridical Foundation The Chemo-Sero-Therapeutic Research Institute | Human anti-amyloid .beta. peptide antibody and fragment of said antibody |
EP1766396B1 (en) | 2004-06-07 | 2010-08-11 | Ramot at Tel-Aviv University Ltd. | Method of passive immunization against disease or disorder characterized by amyloid aggregation with diminished risk of neuroinflammation |
SE0401601D0 (sv) | 2004-06-21 | 2004-06-21 | Bioarctic Neuroscience Ab | Protofibril specific antibodies and uses thereof |
MX2007001679A (es) | 2004-08-09 | 2007-05-23 | Elan Pharm Inc | Prevencion y tratamiento de la enfermedad sinucleinopatica y amiloidogenica. |
WO2006050041A2 (en) | 2004-10-28 | 2006-05-11 | Ramot At Tel Aviv University Ltd. | Methods for reducing or inhibiting brain inflammation or for promoting neurogenesis |
JP2008524247A (ja) | 2004-12-15 | 2008-07-10 | エラン ファーマ インターナショナル リミテッド | 認知の改善における使用のためのアミロイドβ抗体 |
ES2396555T3 (es) | 2004-12-15 | 2013-02-22 | Janssen Alzheimer Immunotherapy | Anticuerpos que reconocen péptido beta amiloide |
BRPI0608076A2 (pt) | 2005-03-05 | 2009-11-10 | Abbott Gmbh & Co Kg | método de seleção, processo para purificação de oligÈmeros beta-a não difusìveis, anticorpos seletivos contra os ditos oligÈmeros beta-a não difusìveis e um processo para fabricação dos ditos anticorpos |
JP2006265189A (ja) | 2005-03-24 | 2006-10-05 | Kyoto Univ | βアミロイドペプチド、及びそれを用いたアルツハイマー病治療薬又は予防薬のスクリーニング方法 |
ES2318918B1 (es) | 2005-04-01 | 2010-02-16 | Biotherapix Molecular Medicines, S.L.U. | Anticuerpos humanos con capacidad de union al peptido beta-amiloide y sus aplicaciones. |
WO2006116192A2 (en) * | 2005-04-21 | 2006-11-02 | Medarex, Inc. | Irta-1 antibodies and their uses |
MY148086A (en) | 2005-04-29 | 2013-02-28 | Rinat Neuroscience Corp | Antibodies directed against amyloid-beta peptide and methods using same |
ITMI20050912A1 (it) | 2005-05-19 | 2006-11-20 | Erregierre Spa | Processo di preparazione di acidi 3-a-ya(b)-diidrossi-6-a(b)-alchil-5b-colanici |
WO2007011907A2 (en) | 2005-07-19 | 2007-01-25 | University Of Rochester | Alpha-synuclein antibodies and methods related thereto |
WO2007021255A1 (en) | 2005-08-09 | 2007-02-22 | Elan Pharmaceuticals, Inc. | Antibodies to alpha-synuclein |
JP2009521403A (ja) | 2005-11-14 | 2009-06-04 | ザ・トラスティーズ・オブ・コランビア・ユニバーシティー・イン・ザ・シティー・オブ・ニューヨーク | Mriによる神経発生の相関の画像法 |
EP1951892A4 (en) | 2005-11-22 | 2009-01-14 | Univ Pennsylvania | ANTIBODY TREATMENT OF MORBUS ALZHEIMER AND RELATED DISEASES |
CN102898519B (zh) | 2005-11-30 | 2015-10-28 | Abbvie公司 | 抗淀粉样β蛋白的单克隆抗体及其用途 |
JP2009518010A (ja) | 2005-11-30 | 2009-05-07 | アボット・ラボラトリーズ | ヒトβアミロイドタンパク質の組み換え形態の調製方法及びこれらのタンパク質の使用 |
EP2289909B1 (en) | 2005-11-30 | 2014-10-29 | AbbVie Inc. | Screening method, process for purifying of non-diffusible a-beta oligomers, selective antibodies against said non-diffusible a-beta oligomers and a process for manufacturing of said antibodies |
PT2361638E (pt) | 2005-12-12 | 2014-04-17 | Ac Immune Sa | Anticorpos monoclonais específicos beta 1-42 com propriedades terapêuticas |
US8784810B2 (en) | 2006-04-18 | 2014-07-22 | Janssen Alzheimer Immunotherapy | Treatment of amyloidogenic diseases |
US8455626B2 (en) | 2006-11-30 | 2013-06-04 | Abbott Laboratories | Aβ conformer selective anti-aβ globulomer monoclonal antibodies |
CA2674140C (en) | 2007-01-05 | 2018-05-15 | University Of Zurich | Method of providing disease-specific binding molecules and targets |
IL199534A (en) | 2007-01-05 | 2013-01-31 | Univ Zuerich | An isolated human antibody capable of detecting a neoepitope in a disease-related protein, a polynucleotide encoding an antibody, a vector containing the polynucleotide, a host cell containing the polynucleotide or vector, a preparation containing the antibody and related methods and uses. |
PL2118300T3 (pl) | 2007-02-23 | 2015-11-30 | Prothena Biosciences Ltd | Zapobieganie i leczenie synukleinopatii i amyloidozy |
RU2488593C2 (ru) | 2007-03-13 | 2013-07-27 | Юниверсити Оф Цюрих | Человеческое опухолеспецифическое моноклональное антитело |
AU2008242648B2 (en) | 2007-04-18 | 2013-09-12 | Janssen Alzheimer Immunotherapy | Prevention and treatment of cerebral amyloid angiopathy |
US8003097B2 (en) | 2007-04-18 | 2011-08-23 | Janssen Alzheimer Immunotherapy | Treatment of cerebral amyloid angiopathy |
WO2008148884A1 (en) * | 2007-06-08 | 2008-12-11 | Universite De La Mediterranee | Compositions and methods for treating pancreatic tumors |
JP5889529B2 (ja) | 2007-07-27 | 2016-03-22 | ヤンセン・サイエンシズ・アイルランド・ユーシー | アミロイド原性疾患の処置 |
US9370531B2 (en) | 2007-08-31 | 2016-06-21 | New York University | Method of providing patient specific immune response in amyloidoses and protein aggregation disorders |
WO2009033743A1 (en) | 2007-09-13 | 2009-03-19 | University Of Zurich Prorektorat Forschung | Monoclonal amyloid beta (abeta)-specific antibody and uses thereof |
US8828382B2 (en) | 2007-09-26 | 2014-09-09 | U3 Pharma Gmbh | Heparin-binding epidermal growth factor-like growth factor binding proteins |
SG185316A1 (en) | 2007-10-19 | 2012-11-29 | Immunas Pharma Inc | ANTIBODY CAPABLE OF SPECIFICALLY BINDING TO Aβ OLIGOMER, AND USE THEREOF |
GB0720912D0 (en) | 2007-10-25 | 2007-12-05 | Univ Cardiff | Monoclonal Anitbody for APP |
NZ585000A (en) | 2007-10-29 | 2012-08-31 | Inst Nat Sante Rech Med | New antibodies specific of the beta-amyloid peptides and their uses as diagnostic agents or drugs |
EP3257865A1 (en) | 2007-11-16 | 2017-12-20 | The Rockefeller University | Antibodies specific for the protofibril form of beta-amyloid protein |
US8414893B2 (en) * | 2007-12-21 | 2013-04-09 | Amgen Inc. | Anti-amyloid antibodies and uses thereof |
AT506535B1 (de) * | 2008-02-22 | 2010-04-15 | Affiris Forschungs & Entwicklungs Gmbh | Vaccine enthaltend alpha-synuclein-mimotope auf basis von peptiden |
TR201901497T4 (tr) | 2008-04-29 | 2019-02-21 | Bioarctic Ab | Alfa-sinüklein ile ilişkili bozukluklar için terapötik ve teşhis yöntemlerinde kullanıma yönelik antikorlar ve aşılar. |
AU2009269700B2 (en) | 2008-07-09 | 2015-07-16 | University Of Zurich | Method of promoting neurogenesis |
WO2010057020A2 (en) | 2008-11-13 | 2010-05-20 | Modgene, Llc | Modification of amyloid-beta load in non-brain tissue |
JP5015984B2 (ja) * | 2009-03-18 | 2012-09-05 | 株式会社コナミデジタルエンタテインメント | ゲームサーバ、ゲームシステム、ゲーム装置、巡回地点更新方法、および、プログラム |
US20100256596A1 (en) | 2009-04-07 | 2010-10-07 | Cabochon Aesthetics, Inc. | Fiber growth promoting implants for reducing the appearance of cellulite |
CN102459335B (zh) | 2009-04-17 | 2015-11-25 | 伊缪纳斯制药株式会社 | 特异性结合Aβ寡聚体的抗体及其用途 |
US8613924B2 (en) | 2009-08-06 | 2013-12-24 | Immunas Pharma, Inc. | Antibodies that specifically bind to A beta oligomers and use thereof |
EP2462161B1 (en) | 2009-08-06 | 2017-03-08 | Immunas Pharma, Inc. | Antibodies that specifically bind to a beta oligomers and use thereof |
KR20120092105A (ko) | 2009-09-02 | 2012-08-20 | 이 아이 듀폰 디 네모아 앤드 캄파니 | 개선된 발유성을 갖는 폴리에스테르 필름 |
BR112013033258B1 (pt) | 2011-06-23 | 2022-09-20 | University Of Zurich | Anticorpo isolado ou fragmento de ligação ao antígeno do mesmo que se liga a alfasinucleína, composição e seus usos |
JP6263473B2 (ja) | 2011-11-02 | 2018-01-31 | バイオジェン インターナショナル ニューロサイエンス ゲーエムベーハー | 脳における高レベルのα−シヌクレインを診断するための抗α−シヌクレイン抗体の使用 |
ITRM20120383A1 (it) | 2012-03-20 | 2013-09-21 | Uni Degli Studi Di Milano B Icocca | Metodo e kit per la rivelazione di anticorpi. |
-
2012
- 2012-06-22 BR BR112013033258-1A patent/BR112013033258B1/pt active IP Right Grant
- 2012-06-22 KR KR1020147001723A patent/KR101976887B1/ko active IP Right Grant
- 2012-06-22 LT LTEP12802721.6T patent/LT2723379T/lt unknown
- 2012-06-22 CN CN201280039104.2A patent/CN103796679B/zh active Active
- 2012-06-22 MX MX2014000054A patent/MX357193B/es active IP Right Grant
- 2012-06-22 CA CA2839563A patent/CA2839563C/en active Active
- 2012-06-22 DK DK12802721.6T patent/DK2723379T3/en active
- 2012-06-22 JP JP2014517198A patent/JP2014528695A/ja not_active Withdrawn
- 2012-06-22 EA EA201391761A patent/EA030777B9/ru unknown
- 2012-06-22 PT PT12802721T patent/PT2723379T/pt unknown
- 2012-06-22 AU AU2012272790A patent/AU2012272790B2/en active Active
- 2012-06-22 EP EP12802721.6A patent/EP2723379B1/en active Active
- 2012-06-22 SI SI200831997T patent/SI2723379T1/sl unknown
- 2012-06-22 PL PL12802721T patent/PL2723379T3/pl unknown
- 2012-06-22 TR TR2018/15563T patent/TR201815563T4/tr unknown
- 2012-06-22 HU HUE12802721A patent/HUE041391T2/hu unknown
- 2012-06-22 WO PCT/US2012/043701 patent/WO2012177972A1/en active Application Filing
- 2012-06-22 US US14/128,497 patent/US9580493B2/en active Active
- 2012-06-22 ES ES12802721T patent/ES2699801T3/es active Active
-
2013
- 2013-12-19 ZA ZA2013/09623A patent/ZA201309623B/en unknown
- 2013-12-19 IL IL230028A patent/IL230028B/en active IP Right Grant
-
2016
- 2016-08-16 JP JP2016159621A patent/JP6302517B2/ja active Active
-
2017
- 2017-01-19 US US15/410,128 patent/US9975947B2/en active Active
-
2018
- 2018-03-07 US US15/914,110 patent/US10301381B2/en active Active
- 2018-09-28 HR HRP20181553TT patent/HRP20181553T1/hr unknown
- 2018-12-10 CY CY20181101312T patent/CY1121392T1/el unknown
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2005060641A2 (en) * | 2003-12-15 | 2005-07-07 | Alexion Pharmaceuticals, Inc. | Engineered templates and their use in single primer amplification |
WO2010032059A2 (en) * | 2008-09-19 | 2010-03-25 | Medimmune Llc | Targeted binding agents directed to cd105 and uses thereof |
WO2010069603A1 (en) * | 2008-12-19 | 2010-06-24 | Neurimmune Therapeutics Ag | Human anti-alpha-synuclein autoantibodies |
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN103796679B (zh) | 抗-α突触核蛋白结合分子 | |
JP6841449B2 (ja) | トランスサイレチン(ttr)アミロイドーシスに対する抗体療法及びそのためのヒト由来抗体 | |
CN102317316B (zh) | 人抗α突触核蛋白自身抗体 | |
CN105324394B (zh) | 人抗-tau抗体 | |
CN103380145B (zh) | 人类抗-sod1抗体 | |
CN104159918B (zh) | Tdp-43特异性结合分子 | |
JP2021003100A (ja) | ヒト由来抗ハンチンチン(htt)抗体及びその使用 | |
EA031698B1 (ru) | Человеческие анти-тау антитела | |
CN108064248A (zh) | 人源抗二肽重复(dpr)抗体 | |
US11542322B2 (en) | Nano-theranostics for Parkinson's disease | |
BRPI0923157B1 (pt) | Anticorpos anti-alfa-sinucleína e seus fragmentos, seus usos e método de preparação, composição compreendendo-os, bem como kit e métodos para o diagnóstico e monitoramento de uma doença sinucleinopática | |
NZ618914B2 (en) | Anti-alpha synuclein binding molecules |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C53 | Correction of patent of invention or patent application | ||
CB02 | Change of applicant information |
Address after: Swiss Shi Lilun Applicant after: BIOGEN IDEC INTERNAT NEUROSCIENCE GMBH Applicant after: Univ Zuerich Address before: Swiss Shi Lilun Applicant before: Panima Pharmaceuticals AG Applicant before: Univ Zuerich |
|
COR | Change of bibliographic data |
Free format text: CORRECT: APPLICANT; FROM: BIOGEN IDEC INTERNATIONAL NEUROSCIENCE GMBH TO: BIOGEN INTERNATIONAL NEUROSCIENCE GMBH Free format text: CORRECT: ADDRESS; FROM: |
|
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
CP02 | Change in the address of a patent holder | ||
CP02 | Change in the address of a patent holder |
Address after: Swiss Swiss Co-patentee after: Univ Zuerich Patentee after: BIOGEN IDEC INTERNAT NEUROSCIENCE GMBH Address before: Swiss Shi Lilun Co-patentee before: Univ Zuerich Patentee before: BIOGEN IDEC INTERNAT NEUROSCIENCE GMBH |